A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE.
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: John C. Byrd, Jacqueline Claudia Barrientos, Stephen Devereux, Jennifer R. Brown, Neil E. Kay, Nishitha M. Reddy, Susan Mary O'Brien, Thomas J. Kipps, Richard R. Furman, Stephen J. Schuster, Adrian Bloor, Devinder Singh Gill, Patrick Thornton, Claire E. Dearden, Ulrich Jäger, Christine Barker, Jennifer Lin, Lori A. Kunkel, Danelle Frances James, Peter Hillmen
Institutions: The Ohio State University, Long Island Jewish Medical Center, King's College London, Dana-Farber Cancer Institute, Mayo Clinic, Vanderbilt University Medical Center, The University of Texas MD Anderson Cancer Center, Moores Cancer Center, Weill Cornell Medicine, Hospital of the University of Pennsylvania, The Christie Hospital, The Christie NHS Foundation Trust, Princess Alexandra Hospital, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Medical University of Vienna, Pharmacyclics (United States), St James's University Hospital
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2287900447